# Quantum-Aided Drug Design for Inhibiting Protein-Protein Interactions for Emerging Threats

### Introduction

- The DARPA IMPAQT ARC Opportunity solicited ideas to explore the following question: What are the applications for a quantum system with N*q > 10,000 as a co-processor for a classical computational system?

- DARPA contracted PolarisQB to expand our Quantum-Aided Drug Design (QuADD) for inhibiting protein-protein interactions (PPIs) for emerging threats.

### Advances

- Quantum utility: QAOA continually discovers unique optimal molecules at a steady rate while the classical sampler struggles to find new molecules
- Links to details on Sextant and our hybrid quantum QAOA sampler
- To learn about our wet lab results for small molecules generated with quantum computers, [contact us.](https://polarisqb.com/contact-us/)

[TO DOWNLOAD THE ONE PAGER AS A PDF CLICK HERE](https://polarisqb.com/wp-content/uploads/2025/02/IMPAQT-final-report-one-pager-FINAL0125.pdf "TO DOWNLOAD THE ONE PAGER AS A PDF CLICK HERE")

Authors: Petroff, Anna B.; Benson, Maurice; Byler, Kendall; Ingman, Victoria; Villar, Santiago; Hendrix, Paul; Simpson, William C.; Goldhagen, Guy; Shipman, William J.; Keinan, Shahar

Published On: January 12th, 2025
Categories: [News](https://polarisqb.com/category/polaris-news/)
Tags: [White Paper](https://polarisqb.com/tag/white-paper/)